| Medtronic Eyes New Product Stream Medical-device maker Medtronic Inc. expects to release 60 "major" products during the fiscal year that runs through next April and isn't eying large-scale acquisitions, the company's chairman said Monday. online.wsj.com |
Five Key Factors Weighing on Dendreon Michael Becker submits:Shares of Dendreon Corporation (DNDN) have declined significantly from an all-time high of $57.67 in late April 2010 when the company received U.S. Food and Drug Administration [FDA] approval for Provenge® [sipuleucel-T], the first active immunotherapy approved for the treatment of cancer in the U.S. On Thursday, shares of Dendreon traded as low as $28.01, down more than 50% from their high, prompting us to briefly review some of the key factors weighing on the company at this time.Product pricing and reimbursementComplete Story » seekingalpha.com |
Cord Blood America CEO Updates Investors on Financial Developments and Stem Cell News in Interview (PR Newswire) Cord Blood America, Inc. , the umbilical cord blood stem cell preservation company focused on bringing the life saving potential of stem cells, a biological insurance policy, to families nationwide and internationally, today announced that CEO Matt Schissler was interviewed recently by Tom Allinder of InBoundMarketingPR. us.rd.yahoo.com |
Egg Probe Tracks Tainted Feed Early tests suggested chicken feed may have become contaminated after it arrived at the Iowa farm at the center of a huge egg recall, helping investigators zero in on the cause of this summer's salmonella outbreak. online.wsj.com |
Amarin Has All the Makings of an Attractive Acquisition Target M.E. Garza submits: By Patrick CrutcherAmarin (AMRN) announced very positive results from their Phase 3 MARINE trial with AMR-101. The drug was effective in reducing triglycerides and was LDL-C neutral. We see them as an attractive takeover target going into 2011.Complete Story » seekingalpha.com |